Jump to main content
Jump to site search

Issue 87, 2015
Previous Article Next Article

A dendritic β-galactosidase-responsive folate–monomethylauristatin E conjugate

Author affiliations

Abstract

We report the study of a new drug delivery system programmed for the selective internalisation and the subsequent enzyme-catalysed release of two monomethylauristatin E molecules inside FR-positive cancer cells. This targeting device is the most potent β-galactosidase-responsive folate–drug conjugate developed so far, killing cancer cells expressing a medium level of FR at low nanomolar concentrations.

Graphical abstract: A dendritic β-galactosidase-responsive folate–monomethylauristatin E conjugate

Back to tab navigation

Supplementary files

Publication details

The article was received on 27 Jun 2015, accepted on 08 Sep 2015 and first published on 08 Sep 2015


Article type: Communication
DOI: 10.1039/C5CC05294G
Citation: Chem. Commun., 2015,51, 15792-15795
  •   Request permissions

    A dendritic β-galactosidase-responsive folate–monomethylauristatin E conjugate

    J. Alsarraf, E. Péraudeau, P. Poinot, I. Tranoy-Opalinski, J. Clarhaut, B. Renoux and S. Papot, Chem. Commun., 2015, 51, 15792
    DOI: 10.1039/C5CC05294G

Search articles by author

Spotlight

Advertisements